Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Ariad Pharmaceuticals, Inc.
Positive early phase II results reported on advanced sarcoma therapy
June 15th, 2005
Ariad Pharmaceuticals, Inc., (ARIA) announced, for the first time, that its mTOR inhibitor, AP23573, administered as a single agent, provides striking clinical benefit and symptomatic improvement in advanced sarcoma patients across multiple sarcoma subtypes in an ongoing phase II multicenter clinical trial. Almost all the patients had failed alternative anticancer treatments and had progressive disease upon entering the trial. Generally, these patients have a median life expectancy of about 1 year. The trial began patient enrollment 7 months ago in October 2004. Eighty-two patients have been enrolled, followed by a pause in enrollment specified in...
Source: Physician Law Weekly (2005-06-15)
|
